Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • 2025
  • Page 525
global-collaboration-set-to-offer-premier-osteopathy-training
Posted inBiotechnology

Global Collaboration Set to Offer Premier Osteopathy Training

January 7, 2025
The University of Plymouth and International Osteopathic Education (IOE) are embarking on an innovative partnership aimed at revolutionizing osteopathic education…
Read More
abbvie-exercises-first-$40-million-option-to-advance-capsida-partnered-cns-gene-therapy
Posted inBiotechnology

AbbVie exercises first $40 million option to advance Capsida-partnered CNS gene therapy

January 7, 2025
Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised…
Read More
novo-nordisk-and-variant-set-out-to-find-new-metabolic-treatments,-pay-communities-that-share-genetic-data
Posted inBiotechnology

Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data

January 7, 2025
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to…
Read More
metsera-links-glp-1-drug-to-11%-weight-loss-after-12-weeks,-teeing-up-trial-of-monthly-dosing
Posted inBiotechnology

Metsera links GLP-1 drug to 11% weight loss after 12 weeks, teeing up trial of monthly dosing

January 7, 2025
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to…
Read More
aviceda-raises-$207m-series-c-to-take-geographic-atrophy-drug-through-phase-3
Posted inBiotechnology

Aviceda raises $207M series C to take geographic atrophy drug through phase 3

January 7, 2025
Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this…
Read More
candid’s-t-cell-engager-shopping-spree-rolls-on-with-wuxi-biologics-pact-worth-up-to-$925m
Posted inBiotechnology

Candid’s T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M

January 7, 2025
Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925…
Read More
ucla-researchers-discover-genetic-markers-for-early-detection-of-adolescent-psychosis
Posted inBiotechnology

UCLA Researchers Discover Genetic Markers for Early Detection of Adolescent Psychosis

January 7, 2025
In a groundbreaking interview featured in Genomic Press, Dr. Carrie E. Bearden, a distinguished Professor of Psychiatry and Biobehavioral Sciences…
Read More
rival-abbvie-and-denali-prospects-flunk-phase-2/3-als-tests,-denting-hopes-for-shared-mechanism
Posted inBiotechnology

Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism

January 7, 2025
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit.…
Read More
revolutionary-ram:-the-future-of-memory-technology-with-enhanced-energy-efficiency
Posted inBiotechnology

Revolutionary RAM: The Future of Memory Technology with Enhanced Energy Efficiency

January 7, 2025
In recent years, the landscape of memory technologies has evolved significantly, driven by the insatiable demand for speed and efficiency…
Read More
cytomx-lays-off-40%-of-staff,-questions-future-of-amgen-partnered-t-cell-engager
Posted inBiotechnology

CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager

January 7, 2025
CytomX Therapeutics is shrinking its head count by 40% as the biotech regroups and looks at fresh ways to conserve…
Read More

Posts pagination

Previous page 1 … 523 524 525 526 527 … 541 Next page

Privacy Policy    Terms

Scroll to Top